

Frankel (Clark (MA))	Lofgren (Jeffries)	Richmond (Butterfield)
Garamendi (Sherman)	Lowenthal (Beyer)	Rouda (Aguilar)
Gonzalez (TX) (Gomez)	McEachin (Wexton)	Roybal-Allard (Garcia (TX))
Grijalva (Garcia (IL))	McNerney (Raskin)	Ruiz (Dingell)
Haaland (Davids (KS))	Meng (Clark (MA))	Rush (Underwood)
Hastings (Wasserman Schultz)	Mitchell (Spanberger)	Ryan (Kildee)
Heck (Kildee)	Moore (Beyer)	Schakowsky
Jayapal (Raskin)	Moulton (McGovern)	Schneider (Casten (IL))
Johnson (TX) (Jeffries)	Mucarsel-Powell (Wasserman Schultz)	Schrier (Spanberger)
Kelly (IL) (Clarke (NY))	Nadler (Jeffries)	Serrano (Jeffries)
Kennedy (McGovern)	Napolitano (Correa)	Sewell (AL) (Cicilline)
Khanna (Sherman)	Neal (Lynch)	Shimkus (Pallone)
Kilmer (Kildee)	Neguse (Perlmutter)	Sires (Pallone)
Kim (Davids (KS))	Pascarell (Pallone)	Smith (WA) (Courtney)
Kirkpatrick (Stanton)	Payne (Wasserman Schultz)	Speier (Scanlon)
Lamb (Sherrill)	Peters (Kildee)	Thompson (MS) (Fudge)
Langevin (Lynch)	Peterson (McCollum)	Titus (Connolly)
Lawrence (Kildee)	Pingree (Cicilline)	Vargas (Correa)
Lawson (FL) (Demings)	Pocan (Raskin)	Veasey (Beyer)
Lieu, Ted (Beyer)	Porter (Wexton)	Velázquez (Clarke (NY))
Lipinski (Schrader)	Price (NC) (Butterfield)	Watson Coleman (Pallone)
		Welch (McGovern)
		Wilson (FL) (Hayes)

PURPLE BOOK CONTINUITY ACT OF 2019

The SPEAKER pro tempore. Pursuant to the adoption of House Resolution 1271, the Senate amendment to H.R. 1520 is considered as agreed to with an amendment consisting of the text of the Rules Committee Print 116-69.

Senate amendment:

Strike all after the enacting clause and insert the following:

SECTION 1. SHORT TITLE.

The Act may be cited as the "Purple Book Continuity Act of 2020".

SEC. 2. BIOLOGICAL PRODUCT PATENT TRANSPARENCY.

(a) IN GENERAL.—Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) is amended by adding at the end the following:

"(9) PUBLIC LISTING.—

"(A) IN GENERAL.—

"(i) INITIAL PUBLICATION.—Not later than 180 days after the date of enactment of the Purple Book Continuity Act of 2020, the Secretary shall publish and make available to the public in a searchable, electronic format—

"(I) a list of each biological product, by non-proprietary name (proper name), for which, as of such date of enactment, a biologics license under subsection (a) or this subsection is in effect, or that, as of such date of enactment, is deemed to be licensed under this section pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009;

"(II) the date of licensure of the marketing application and the application number; and

"(III) with respect to each biological product described in subclause (I), the licensure status, and, as available, the marketing status.

"(ii) REVISIONS.—Every 30 days after the publication of the first list under clause (i), the Secretary shall revise the list to include each biological product which has been licensed under subsection (a) or this subsection during the 30-day period or deemed licensed under this section pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009.

"(iii) PATENT INFORMATION.—Not later than 30 days after a list of patents under subsection

(l)(3)(A), or a supplement to such list under subsection (l)(7), has been provided by the reference product sponsor to the subsection (k) applicant respecting a biological product included on the list published under this subparagraph, the reference product sponsor shall provide such list of patents (or supplement thereto) and their corresponding expiry dates to the Secretary, and the Secretary shall, in revisions made under clause (ii), include such information for such biological product. Within 30 days of providing any subsequent or supplemental list of patents to any subsequent subsection (k) applicant under subsection (l)(3)(A) or (l)(7), the reference product sponsor shall update the information provided to the Secretary under this clause with any additional patents from such subsequent or supplemental list and their corresponding expiry dates.

"(iv) LISTING OF EXCLUSIVITIES.—For each biological product included on the list published under this subparagraph, the Secretary shall specify each exclusivity period under paragraph (6) or paragraph (7) for which the Secretary has determined such biological product to be eligible and that has not concluded.

"(B) REVOCATION OR SUSPENSION OF LICENSE.—If the license of a biological product is determined by the Secretary to have been revoked or suspended for safety, purity, or potency reasons, it may not be published in the list under subparagraph (A). If such revocation or suspension occurred after inclusion of such biological product in the list published under subparagraph (A), the reference product sponsor shall notify the Secretary that—

"(i) the biological product shall be immediately removed from such list for the same period as the revocation or suspension; and

"(ii) a notice of the removal shall be published in the Federal Register."

(b) REVIEW AND REPORT ON TYPES OF INFORMATION TO BE LISTED.—Not later than 3 years after the date of enactment of this Act, the Secretary of Health and Human Services shall—

(1) solicit public comment regarding the type of information, if any, that should be added to or removed from the list required by paragraph (9) of section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), as added by subsection (a); and

(2) transmit to Congress an evaluation of such comments, including any recommendations about the types of information that should be added to or removed from the list.

The text of the House amendment to the Senate amendment is as follows:

In lieu of the matter proposed to be inserted by the Senate, insert the following:

That the Continuing Appropriations Act, 2021 (division A of Public Law 116-159) is further amended by striking the date specified in section 106(3) and inserting "December 28, 2020".

This Act may be cited as the "Further Extension of Continuing Appropriations Act, 2021".

MESSAGE FROM THE SENATE

A message from Senate by Ms. Byrd, one of its clerks, announced that the Senate has passed a bill of the following title in which the concurrence of the House is requested:

S. 371. An act to provide regulatory relief to charitable organizations that provide housing assistance, and for other purposes.

COMMUNICATION FROM THE CLERK OF THE HOUSE

The SPEAKER pro tempore (Mr. BROWN of Maryland) laid before the

House the following communication from the Clerk of the House of Representatives:

OFFICE OF THE CLERK,
HOUSE OF REPRESENTATIVES,
Washington, DC, December 21, 2020.

Hon. NANCY PELOSI,
The Speaker, House of Representatives,
Washington, DC.

DEAR MADAM SPEAKER: Pursuant to the permission granted in Clause 2(h) of Rule II of the Rules of the U.S. House of Representatives, the Clerk received the following message from the Secretary of the Senate on December 21, 2020, at 1:24 p.m.:

That the Senate passed S. 2346.
That the Senate passed S. 2716.
That the Senate passed S. 2827.
That the Senate passed S. 3099.
That the Senate passed S. 3100.
That the Senate passed S. 3948.
That the Senate passed S. 3952.
That the Senate passed S. 4556.
That the Senate passed S. 5076.
That the Senate passed without amendment H.R. 1240.

That the Senate passed without amendment H.R. 4031.

That the Senate passed without amendment H.R. 5458.

That the Senate passed without amendment H.R. 5852.

That the Senate passed without amendment H.R. 6535.

That the Senate passed without amendment H.R. 7460.

With best wishes, I am,

Sincerely,

CHERYL L. JOHNSON,
Clerk.

DIRECTING THE CLERK OF THE HOUSE OF REPRESENTATIVES TO MAKE A CORRECTION IN THE ENROLLMENT OF H.R. 133

Mrs. LOWEY. Mr. Speaker, I send to the desk a concurrent resolution and ask unanimous consent for its immediate consideration in the House.

The Clerk read the title of the concurrent resolution.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from New York?

There was no objection.

The text of the concurrent resolution is as follows:

H. CON. RES. 127

Resolved by the House of Representatives (the Senate concurring), That, in the enrollment of the bill H.R. 133 the Clerk of the House of Representatives shall make the following correction:

Amend the title so as to read: "Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes."

The concurrent resolution was agreed to.

A motion to reconsider was laid on the table.

DIRECTING THE CLERK OF THE HOUSE OF REPRESENTATIVES TO MAKE A CORRECTION IN THE ENROLLMENT OF H.R. 1520

Mrs. LOWEY. Mr. Speaker, I send to the desk a concurrent resolution and ask unanimous consent for its immediate consideration in the House.